Results 71 to 80 of about 5,736 (192)

Comparison of Efficacy, Safety, and Humanistic Outcomes of Iron-Chelation Therapy in Pediatrics Suffering from Transfusion-Dependent β-Thalassemia Major

Indian Journal of Medical Specialities, 2020
Introduction: Beta-thalassemia major (β-TM) is a severe form of genetic disorder that affects the patient's quality of life. Iron-chelation therapy (ICT) is recommended in these patients to reduce the complications (iron overload) associated with ...
Narayana Goruntla, P. Stephen Azarya, Mahitha Chalagundla, Dasaratha Ramaiah Jinka, Pradeepkumar Bhupalam, Vishnuvandana Bandaru   +5 more
doaj   +1 more source

In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington's Disease

Movement Disorders, Volume 41, Issue 5, Page 1257-1267, May 2026.
Abstract Background The pathophysiology of Huntington's disease (HD) remains obscure. Magnetic resonance imaging (MRI) can reveal in vivo molecular changes related to disease pathology. Objectives To investigate catecholaminergic neuronal integrity and subcortical brain iron accumulation in HD employing neuromelanin‐sensitive MRI, and quantitative ...
Edoardo R. de Natale, Heather Wilson, Efstratios Karavasilis, Athanasia Liozidou, Chrisoula Kartanou, Georgios Velonakis, Jens Kuhle, Ioannis Zalonis, Georgia Karadima, Leonidas Stefanis, Georgios Koutsis, Marios Politis   +11 more
wiley   +1 more source

Effect of deferiprone in transwell-cultured confluent ECC-1 cells: Epithelial monolayer integrity.

, 2016
Cultures at maximal luminal barrier function (TER ≥ 1000 ohms / cm2) were left untreated, or were treated with deferiprone at the indicated concentrations, every day via the apical chamber and every other day via the basolateral chamber.
Myung Hee Park (176990), Bernadette M. Cracchiolo (462186), Paul E. Palumbo (462178), Michael Spino (462182), John Connelly (462188), Bart Holland (462191), Tsafi Pe’ery (462192), Axel-Rainer Hanauske (462179), Jonathan Karn (220557), Hartmut M. Hanauske-Abel (462176), Deepti Saxena (462177), Michael B. Mathews (35045), Fernando Tricta (462187), Darlene D’Alliessi Gandolfi (2793712)   +13 more
core   +1 more source

Solubility determination and thermodynamic modeling of deferiprone in the binary aqueous mixtures of 2-propanol from 293.15 to 313.15 K: Deferiprone dissolution in the aqueous mixtures of 2-propanol

, 2023
In the current work, solid-liquid equilibrium measurements and data correlations of deferiprone in 2-propanol + water were carried out. Mathematical models (van’t Hoff, λh, modified Wilson, Jouyban-Acree, and Jouyban-Acree-van’t Hoff) were utilized for ...
Rahimpour, Elaheh, Jouyban , Abolghasem, Rezaei , Homa, Martinez , Fleming   +3 more
core   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, Volume 59, Issue 5, May 2026.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

FBS0701 treatment chelates intracellular erythrocytic iron to the same extent as deferiprone but unlike deferiprone, removes iron from erythrocytes.

, 2013
Aliquots 1–5×106 erythrocytes from two separate healthy donors were stained in the dark with 0.125 µM calcein-AM for 15 minutes at 37°C. Cells were washed twice with PBS and allowed to rest for 10 minutes at 37°C in the dark.
Patricia Ferrer (322100), Abhai K. Tripathi (322101), Carla Cerami Hand (322105), Hugh Young Rienhoff Jr (322107), David J. Sullivan Jr (322111), Martha A. Clark (322102)   +5 more
core   +1 more source

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

Mediterranean Journal of Hematology and Infectious Diseases, 2020
Background: The four most commonly used chelation regimens for β-thalassemia major patients in China are a combination therapy of deferoxamine and deferiprone (DFO+DFP), deferoxamine(DFO) monotherapy, deferiprone(DFP) monotherapy and deferasirox(DFX ...
Jialian Li
doaj   +1 more source

Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis [PDF]

, 2019
OBJECTIVE: Deferiprone is an iron chelator that has recently been used to treat patients with infratentorial superficial siderosis (iSS). It is considered to have a generally favourable safety profile but concerns have been raised due to the risk of ...
Cowley, P, Sammaraiee, Y, Eleftheriou, P, Hylton, B, Porter, J, Banerjee, G, Werring, DJ, Farmer, S   +7 more
core  

Challenges of Iron Chelation in Thalassemic Children

Thalassemia Reports
Thalassemia treatment still relies on supportive care, mainly including blood transfusion and iron chelation therapy. Iron chelation is considered the main factor responsible for the marked improvement in survival rates of thalassemic patients ...
Alkistis Adramerina, Marina Economou
doaj   +1 more source

Cellular toxicity of LTCC blockers and the comparison with deferiprone.

, 2014
(A) Apoptotic effects of 10 or 100 µM AML, VER and deferiprone on HL-1 cells for 72 hr were assessed by annexin V/PI flow cytometry assay. (B) HL-1 cells were challenged with 300 µM Fe(III) or Fe(II), followed by treatments of 10 or 100 µM deferiprone 20
Shing Chan (659344), Z. Ioav Cabantchik (659343), Yiu-fai Cheung (292747), Godfrey Chi-fung Chan (474934), Mei-pian Chen (659342)   +4 more
core   +1 more source